CA2637350A1 - Method of treatment, prophylaxis and diagnosis of pathologies of the bone - Google Patents

Method of treatment, prophylaxis and diagnosis of pathologies of the bone Download PDF

Info

Publication number
CA2637350A1
CA2637350A1 CA002637350A CA2637350A CA2637350A1 CA 2637350 A1 CA2637350 A1 CA 2637350A1 CA 002637350 A CA002637350 A CA 002637350A CA 2637350 A CA2637350 A CA 2637350A CA 2637350 A1 CA2637350 A1 CA 2637350A1
Authority
CA
Canada
Prior art keywords
bone
gene
subject
list consisting
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002637350A
Other languages
English (en)
French (fr)
Inventor
Anna Kathleen Coussens
Angela Mary Van Daal
Barry Crampton Powell
Peter John Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Womens and Childrens Health Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006900307A external-priority patent/AU2006900307A0/en
Application filed by Individual filed Critical Individual
Publication of CA2637350A1 publication Critical patent/CA2637350A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002637350A 2006-01-20 2007-01-19 Method of treatment, prophylaxis and diagnosis of pathologies of the bone Abandoned CA2637350A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006900307A AU2006900307A0 (en) 2006-01-20 Method of treatment and diagnosis
AU2006900307 2006-01-20
PCT/AU2007/000055 WO2007082352A1 (en) 2006-01-20 2007-01-19 Method of treatment, prophylaxis and diagnosis of pathologies of the bone

Publications (1)

Publication Number Publication Date
CA2637350A1 true CA2637350A1 (en) 2007-07-26

Family

ID=38287201

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002637350A Abandoned CA2637350A1 (en) 2006-01-20 2007-01-19 Method of treatment, prophylaxis and diagnosis of pathologies of the bone

Country Status (8)

Country Link
US (1) US20100330085A1 (https=)
EP (1) EP1991274A4 (https=)
JP (1) JP2009523739A (https=)
CN (1) CN101426536A (https=)
AU (1) AU2007207341B2 (https=)
CA (1) CA2637350A1 (https=)
NZ (1) NZ569697A (https=)
WO (1) WO2007082352A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0707349D0 (en) * 2007-04-17 2007-05-23 Renovo Ltd Medicaments and methods for accelerating wound healing
US20100183514A1 (en) * 2007-05-29 2010-07-22 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
CA2708163A1 (en) * 2007-12-11 2009-06-18 Epigenomics Ag Methods and nucleic acids for analyses of cell proliferative disorders
JP5346957B2 (ja) 2008-01-23 2013-11-20 ヘルレフ ホスピタル 不特定疾患の汎用マーカーとしてのｙｋｌ−４０
WO2010028658A1 (en) 2008-09-15 2010-03-18 Herlev Hospital, Region Hovedstaden Ykl-40 as a marker for gastrointestinal cancers
GB0922085D0 (en) * 2009-12-17 2010-02-03 Cambridge Entpr Ltd Cancer diagnosis and treatment
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
WO2012057697A1 (en) * 2010-10-28 2012-05-03 Modmab Limited Uk Filial New diagnostic and therapeutic target
WO2012096977A1 (en) * 2011-01-10 2012-07-19 The Regents Of The University Of Colorado, A Body Corporate Inhibitors of eya2
WO2012112798A1 (en) * 2011-02-16 2012-08-23 Ma Xiaojing Methods to enhance cell-mediated immunity
AU2012253204A1 (en) * 2011-05-06 2013-04-18 Women's And Children's Health Research Institute Inc Method of treatment and prophylaxis of pathologies of the bone
CN109295218B (zh) * 2018-12-11 2020-05-19 南京医科大学 环状RNA标志物hsa_circ_0001788及其应用
CN114015767B (zh) * 2021-11-18 2023-06-02 南京市儿童医院 一种鉴别颅缝早闭的血清circRNA标志物及其应用
CN114657121B (zh) * 2022-03-23 2023-07-25 新乡医学院 LOX1基因作为流体剪切力作用下BMSCs成骨分化促进剂的应用
CN114774546B (zh) * 2022-04-27 2023-04-18 江苏省人民医院（南京医科大学第一附属医院） 一种与人骨肉瘤相关的分子标记物trim22及其应用
CN116217721B (zh) * 2023-02-16 2026-04-03 复旦大学附属中山医院 一种C14orf78免疫组织化学抗体及其制备方法与应用
TWI901424B (zh) * 2023-11-10 2025-10-11 長庚醫療財團法人林口長庚紀念醫院 抗-pdgfrl中和抗體在治療關節炎上的用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4018884A (en) 1975-06-26 1977-04-19 Hoffmann-La Roche Inc. Fluorogenic materials and labeling techniques
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4744981A (en) 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0329184A3 (en) 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US4988496A (en) 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US6096716A (en) 1994-12-12 2000-08-01 The Board Of Regents, The University Of Texas System Liposome-mediated transfection of central nervous system cells
US20050171012A1 (en) * 2001-09-10 2005-08-04 Takeda Chemical Industries, Ltd. Preventives/remedies for bone/joint diseases
US20050084487A1 (en) * 2002-12-24 2005-04-21 Amgen Inc. Wnt-1 inhibitory factor-1 (WIF-1) molecules and uses thereof
EP1620567A1 (en) * 2003-04-15 2006-02-01 Hans-Jürgen Thiesen Method for diagnosing rheumatoid arthritis or osteoarthritis
JP5068543B2 (ja) * 2004-02-16 2012-11-07 プロテオジス アクチェンゲゼルシャフト がんに関する診断マーカー
US7485657B2 (en) * 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3

Also Published As

Publication number Publication date
NZ569697A (en) 2012-01-12
AU2007207341A1 (en) 2007-07-26
AU2007207341B2 (en) 2012-05-10
EP1991274A1 (en) 2008-11-19
CN101426536A (zh) 2009-05-06
WO2007082352A1 (en) 2007-07-26
JP2009523739A (ja) 2009-06-25
US20100330085A1 (en) 2010-12-30
EP1991274A4 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
AU2007207341B2 (en) Method of treatment, prophylaxis and diagnosis of pathologies of the bone
AU2008286361B2 (en) IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
US7537891B2 (en) Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
EP2420575B1 (en) Marker for prognosis of liver cancer
CA2767914A1 (en) Markers for endometrial cancer
US20120052079A1 (en) Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines
JP2009525041A (ja) 癌またはその素因の早期検出のための方法およびキット
CN105969901B (zh) Ms4a6a作为多发性骨髓瘤诊治标志物的用途
US20130011411A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
CN107012256A (zh) 腹主动脉瘤诊治标志物
CN106011289B (zh) Lilra2基因及其表达产物作为多发性骨髓瘤的诊治靶标
CN107022635B (zh) Acadl基因及其表达产物在制备腹主动脉瘤诊治产品中的应用
CA2589055A1 (en) Methods for assessing patients with acute myeloid leukemia
WO2007044622A1 (en) Use of mif and mif pathway agonists
KR100568724B1 (ko) 담관암 유전자 마커 및 이를 이용한 담관암 진단킷트
CN105969904B (zh) 多发性骨髓瘤生物标志物
CN106947820B (zh) Vcan在结肠腺癌诊治中的用途
CN107012257A (zh) 用于诊治腹主动脉瘤的生物标志物
KR100861464B1 (ko) 발암/전이유전자 ｔｉｐ41과 이에 의해 코드되는 단백질 및이를 이용한 발암 및 전이 진단 키트
CN106381329B (zh) C18orf8基因及其表达产物作为下咽癌的诊治靶标
CN106222257B (zh) Igsf6在制备诊治多发性骨髓瘤产品中的应用
CN106947819B (zh) 结肠腺癌诊治标志物
KR101104105B1 (ko) 대장암 진단용 조성물 및 그 용도
CN107177674A (zh) Sphar作为腹主动脉瘤的诊治靶标
EP1880026B1 (en) Genetic polymorphisms associated with myocardial infarction and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20150120